u/SecondPrevious7385

2 theses · first seen Aug 23, 2026

Window	Theses	Resolved	Wins	Win rate	Avg return	Median return
1d	1	1	1	100%	+1.5%	+1.5%
3d	1	1	0	0%	-0.8%	-0.8%
1w	1	1	1	100%	+2.3%	+2.3%
1m	1	1	0	0%	-12.2%	-12.2%
3m	0	0	0	—	—	—
6m	0	0	0	—	—	—
1y	0	0	0	—	—	—

Past performance does not predict future results. Informational only, not investment advice.

Thesis history

$AIBr/pennystocksDDbullish

u/SecondPrevious7385 · 2d ago1 prior · awaiting results

$AIB — A Small-Cap AI Data Center Play With a $1.32B Nebius Contract

AIB is valued at ~$105M market cap but has secured a $1.32B Nebius contract for 50 MW over 12 years, de-risking customer acquisition. The company owns 120 MW of utility capacity across two sites, can finance CLT1 largely through customer prepayments without heavy common equity dilution, and should prove its model within a year as it phases the first 25 MW into operation.

At post $1.33Now $1.330.0% since postedas of Oct 12, 4:30 PM ET

original post →

$MAIAr/pennystocksDDbullish

u/SecondPrevious7385 · 34d ago1 prior · awaiting results

$MAIA: An $80M Phase 3 oncology company with 17.8-month survival data, heavy insider buying, and partnerships with Regeneron, Roche and BeOne

MAIA is a small-cap oncology company with a Phase 3 trial underway for ateganosine, a first-in-class telomere-targeting immunotherapy showing 17.8-month median survival in Phase 2 (vs. 5-6 months historical chemotherapy). At $80M market cap with partnerships from Regeneron, Roche, and BeOne, success in the randomized Phase 3 trial could drive substantial revaluation in a large, underserved third-line NSCLC market.

At post $1.31Now $1.18-9.9% since postedas of Oct 12, 4:30 PM ET

1d+1.5%

3d-0.8%

1w+2.3%

1m-12.2%

3m—

6m—

1y—

original post →

End of results.